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Abstract
Background—Selective serotonin reuptake inhibitors (SRIs) relieve irritability within days in
women with premenstrual dysphoric disorder (PMDD); however, the effects on other affective
symptoms in PMDD remain to be demonstrated.
Methods—We performed hourly ratings in women with PMDD to test the specificity of the
therapeutic effects of SRIs and to determine whether the kinetics of these effects differ from those
of the symptom offset accompanying menses. Twelve women with PMDD received fluoxetine (20
mg daily) during the luteal phase of the menstrual cycle. Twelve other women with PMDD
received no treatment. Outcome measures included a visual analogue scale completed hourly
before and after either the start of SRIs or at menses-onset in the untreated women and the
premenstrual tension syndrome (PMTS) scale completed daily. Data were analyzed by ANOVA-
R.
Results—Hourly VAS scores significantly improved after SRI in irritability as well as sadness,
anxiety, and mood swings. Compared with the symptomatic pretreatment baseline, PMTS scores
significantly improved on the second day after the start of SRI (p < .01). An identical time course
of symptom improvement occurred after both SRI and menses-onset.
Conclusion and Discussion—These data document that the rapid response to SRI was not
limited to irritability. The similar kinetics in the remission of PMDD after SRIs and after menses-
onset suggest both a phenotype reflecting the relative capacity to rapidly change affective state,
and a possible therapeutic mechanism by which SRIs recruit this endogenous capacity to change
state, normally expressed around menses-onset in women with PMDD.
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INTRODUCTION
The relatively rapid symptom improvement after initiation of serotonin reuptake inhibitors
(SRIs) in severe premenstrual syndrome and premenstrual dysphoric disorder (PMDD; i.e.
within days) has led to the successful use of symptom-onset treatment in women with
PMDD.[1] A study by Landen et al.[2] documented the timing of the onset of therapeutic
action of paroxetine in women with PMDD under double-blind, placebo-controlled
conditions. Compared with placebo, paroxetine significantly improved the symptom of
irritability within 3 days after the start of treatment. These important observations not only
guide clinical practice in this condition, but suggest that the mechanism of action of SRIs in
PMDD differs from that presumed to underlie the therapeutic effects of SRIs in depression
and anxiety disorders. Nonetheless, several characteristics of the rapid therapeutic response
in PMDD remain to be addressed. First, in the study by Landen et al.,[2] although significant
differences in symptom severity between SRI and placebo appeared after 3 days of
treatment, the difference reflected a waning of the improvement in the placebo group
observed during the first and second day of treatment. Indeed, the group data,
notwithstanding, some women with PMDD appeared to respond to SRIs after the first day.
Thus, some women with PMDD could experience improvement within hours of taking SRIs
similar to the symptom response to the serotonergic agent m-CPP reported by Su et al.[3]
Second, since the two hourly symptom ratings were not obtained beyond the first day of
treatment, it is possible that a circadian change in symptom improvement (with possible
morning worsening) was present after the first day that was not detectable by the evening-
only ratings after the first day of treatment. Third, it remains to be demonstrated if the rapid
therapeutic effect of SRIs in PMDD is confined to the symptom of irritability or whether
other affective symptoms in this condition also remit rapidly with SRIs. In the Landen
study,[2] women with PMDD were selected for the presence of prominent irritability, and
only a composite score, which contained a range of both physical and affective symptoms
was employed to monitor response in symptoms other than irritability. In particular, it would
be important clinically to determine if symptoms of sadness and anxiety experienced by
women with PMDD show a similar rapid response to SRIs as that observed for the symptom
of irritability. Finally, it is possible that the kinetics of the “switch-out” (or rapid remission
of symptoms) in PMDD, are similar to those observed at the onset of menses. A rapid
remission of symptoms in PMDD also is observed naturalistically proximate to the onset of
menses and the luteal to follicular phase transition. Previous reports by Bancroft[4] describe
substantial individual variability in the rapidity of symptom remission at menses-onset in
women with PMDD. Similar variability in the response to SRIs also is suggested by Landen
et al.,[2] since some women appeared to respond rapidly within the first two days of
treatment, whereas the group as a whole did not meet criteria for response until after the
third day of treatment. Similar kinetics between the remission of symptoms in PMDD after
SRIs and after the onset of menses could suggest the following: (1) the presence of a
phenotype reflecting the relative capacity to rapidly change affective state; and (2) a possible
therapeutic mechanism by which SRIs activate or “recruit” this endogenous capacity to
change state, normally expressed around the onset of menses.
In this study, we address these questions and document the pattern of acute symptom
response, including irritability, depression, anxiety, and mood swings, to the SRI fluoxetine
in symptomatic women with PMDD during the luteal phase. First, we employ symptom self-
ratings completed on an hourly basis each day over several days of treatment to monitor
kinetics of symptom change in PMDD that precedes the final clinical response to fluoxetine.
Second, we compare the response to fluoxetine of the four core symptoms of PMDD listed
above. Finally, we investigate whether the kinetics of the SRI-induced switch-out differ
from those accompanying menses under nonpharmacological conditions.
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METHODS
SUBJECT SELECTION
We studied 24 women with PMDD admitted to the NIMH Out-patient clinic, 12 received
treatment with fluoxetine and 12 received no treatment. All women were healthy and
reported regular menstrual cycles (i.e. 21–35 days). Prospective participants were screened
with a daily visual analogue scale of self-ratings of affective symptoms (i.e. a 100 mm line
bracketed by severity extremes [none to worst ever] for sadness, irritability, anxiety, and
mood swings).[5] In at least two of three menstrual cycles, women diagnosed with PMDD
showed at least a 30% higher mean level of sadness, irritability, anxiety, or mood swings in
the week before menses compared with the week after the end of menses. (Ratings were
adjusted for the range of the scale employed by dividing 30% by the percent of the scale
spanned by the extreme high and low ratings.) This criterion operationalizes both the DSM-
IV severity and cyclicity criteria for PMDD.[6] Thus, all women met the criteria for PMDD
of the DSM-IV.[7] All participants were given a Structured Clinical Interview for DSM-IV
(SCID),[7] women with PMDD were required to have no current or recent (<2 years) Axis I
condition.
Written informed consent was obtained from each subject for completion of the symptom
ratings and collection of the blood samples. As a part of this protocol, women consented to
receive standard therapy with an SRI.
PROCEDURE
Twelve women with PMDD participated in an open label treatment in which we evaluated
the time course of symptom response after commencing treatment with a 20 mg daily dose
of fluoxetine. Symptom ratings to monitor the daily and hourly change in symptom severity
included the following scales: (1) The Rating Scale for Premenstrual Tension Syndrome
(PMTS), both self and observer (PMTS-Rater) forms, were completed by only those women
with PMDD receiving fluoxetine.[8] The PMTS-Rater was administered only on Days 1, 2,
and 3 to clinically confirm the presence of symptoms by telephone, whereas, PMTS ratings
were completed daily until after the onset of menses. (2) The Hourly Visual Analog Scale
(VAS) was completed by all women with PMDD regardless of treatment group. Participants
were asked to indicate on a 100-mm line the severity of four symptoms commonly
associated with PMDD: anxiety, irritability, sadness, and mood instability. Women rated
themselves on all four symptoms every hour.
The twelve women who were given fluoxetine determined the onset of the LH surge by a
home urinary assay kit, and then monitored the onset of their typical PMDD symptoms with
the Daily Rating Form (DRF).[9] The DRF is a five point Likert-type scale that measures the
severity of common symptoms of PMDD such as sadness, anxiety, irritability, cravings for
food, impaired function, bloating, and breast pain. Scores range from 1 (not at all) to 6
(extreme). Patients were instructed to complete this form each evening based on how they
felt during the previous 12 hr. After the LH surge, women called the clinic on the first day
that they rated a DRF mood symptom severity at two or greater (i.e. minimal symptom
severity). The next morning (Day 1), participants completed the PMTS[8] rating scale.
Additionally, on Day 1 all participants were instructed to complete the hourly VAS ratings
upon wakening and continue ratings until bedtime. After 2 days of symptoms, each woman
started fluoxetine at a dose of 20 mg per day. Participants were instructed to continue ratings
until 2 days after the onset of menses. During the early follicular phase of the next menstrual
cycle, blood samples were obtained for measurement of fluoxetine and norfluoxetine plasma
levels.
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As a comparison group, twelve women with PMDD who did not receive any treatment
completed identical hourly VAS ratings prior to and after menses to permit evaluation of the
time course of symptom change in response to menses (i.e. menses-related switch out of
symptoms). These women who did not receive treatment were asked to complete the hourly
VAS in a similar manner as those receiving treatment except starting 10 days after a positive
LH surge test and continuing until symptoms had ceased for 3 days.
Side effects experienced by the women receiving an SRI were monitored by clinical
assessment only.
DATA ANALYSIS
Treatment response to fluoxetine: to examine the kinetics of the response to SRIs in the
hourly VAS, analysis of variance with repeated measures (ANOVA-Rs) were performed
with VAS symptoms (i.e. irritability, anxiety, depression, and mood instability), day of
treatment (1–5), and hour (1–10) as the within group variables. Hour 1 was the first rating at
the beginning of the day. We included the ratings for the next 10 hr since the number of
hours rated in the evening varied among the women depending on their bedtimes. To avoid
violations of sphericity requirements, Greenhouse–Geisser corrections were used for all P-
values in the ANOVA-Rs.
In each woman, the time taken to achieve a clinical response was defined by the number of
days from the start of fluoxetine treatment until a 50% reduction in PMTS rating scores was
achieved compared with the symptomatic baseline. Additionally, the daily PMTS rating
scores were compared by ANOVA-Rs with time as the within group variable (i.e. days 1
through 5 of treatment). The number of days of ratings that each woman rated varied
depending on when menses started; since all but one woman experienced a 50% or greater
response within 5 days after starting fluoxetine, we analyzed only the first 5 days of
treatment in the ANOVA-R. When indicated by significant ANOVA-R, post hoc Bonferroni
t tests were performed to identify the first day posttreatment on which there was a significant
difference in symptom scores compared with pretreatment baseline. A remission of
symptoms was defined by PMTS scores 5 for three consecutive days,[10] whereas a partial
response was defined by PMTS scores that were ≤50% lower than baseline but did not meet
criteria for remission. Plasma levels of fluoxetine and norfluoxetine were compared by
Students t test between those women who met criteria for remission and those who were
partial responders.
Finally, we compared the hourly VAS symptom ratings after fluoxetine treatment with those
after the onset of menses in untreated women by ANOVA-R with treatment group
(fluoxetine treatment versus no treatment [i.e. onset of menses]), and symptom (anxiety,
irritability, depression, and mood swings), day (1–3), and hour (1–10) as the within subjects
variables. Day 1 was either the first day of fluoxetine treatment or the first day of menses in
the untreated women. We also compared prestudy baseline symptom severity ratings on the
VAS and demographic variables between the treated and untreated groups by ANOVA-R
and Students t test, respectively.
RESULTS
Demographic characteristics of the two groups of women are listed in Table 1. The women
in the SRI treatment group were similar in age and in the numbers of women with a past
history of depression to those in the untreated group (Table 1). The two groups also did not
differ in baseline severity scores for the symptoms of irritability, anxiety, sadness, and mood
swings. One of the women who was treated with fluoxetine completed only 2 days of
ratings. Additionally, five women in the untreated group stopped their ratings before the
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third day postmenses. Nonetheless, since all women reported a substantial improvement in
their ratings during the constricted time period (i.e. the ratings captured the switch-out), we
included their ratings in the respective analyses. SRI was well tolerated by the women in this
trial and none of the women in either the treated or untreated group reported the emergence
of suicidal ideation during the study.
TIME COURSE OF SYMPTOM RESPONSE AFTER SRI
All of the hourly VAS symptoms showed a similar significant improvement after the start of
treatment (i.e. main effect of day F5,50 = 5.9, P = .002), which did not differ across
individual symptoms (Fig. 2.) There also was a significant main effect of hour, which
reflected an improvement in symptom severity from the first to the last rating of the day
regardless of symptom or day of treatment (ANOVA-R: main effect of time F9,90 = 3.1, P
= .04; no significant interaction effects P [range] = .3–.5). A similar pattern of diurnal
symptom improvement also was observed in the untreated women with PMDD after the
onset of menses.
Relative to their baseline, pretreatment scores, women experienced a 50% reduction in
PMTS rating scores within 1 to 6 days after initiating fluoxetine (median = 2 days; mean ±
SD = 2.9 ± 1.6 days). experienced full Seven women remission and five women were partial
responders. Seven women experienced a 50% reduction relative to baseline within 2 days of
treatment (four of whom experienced full remission), one woman after 3 days of treatment,
two women after 4 days, and one each after 5 and 6 days of treatment. ANOVA-R of the
PMTS ratings between Day 1 and Day 5 of treatment showed a significant effect of day
(ANOVA-R: F4,40 = 9.1, P < .001). Post hoc Bonferroni t tests showed that relative to
baseline prior to treatment, there was a significant improvement on the second day after the
start of treatment, which was maintained during the subsequent days until menses
(Bonferroni t = 3.8, df = 40, P < .01) with four comparisons (Fig. 1). The effect size of the
difference between PMTS scores at baseline and after day 5 of SRI treatment was 0.7.
There were no significant differences in plasma levels of fluoxetine and norfluoxetine in the
women who met criteria for remission compared with those who met criteria for a partial
therapeutic response (t10 = 0.03 and 0.4; respectively; P = NS)
SYMPTOM RESPONSES TO SRI AND THE ONSET OF MENSES (Fig. 3)
We observed an identical pattern of symptom improvement in the VAS scores after both
SRI treatment and menses onset. No significant main or interaction effects of group (i.e.
treatment versus onset of menses) were observed in the pattern of symptom response. The
onset of menses and the initiation of SRI treatment were accompanied by an identical
pattern of responses with significant effects of both day and hour that reflected an
improvement in scores after the onset of either treatment or menses (main effect of day F2,32
= 8.3, P = .003; main effect of hour F9,144 = 5.9, P < .001). However, there were no
significant main or interaction effects of group (i.e. SRI versus menses; main effect of group
F1,16 = 2.3, P = NS) with the exception of a trend for a significant symptom × day × group
interaction (F6,96 = 3.2, P = .05), which reflected a relatively blunted improvement in the
symptom of mood instability in the unmedicated women whose symptom ratings were
monitored around menses compared with those receiving SRI. Finally, there were no
significant interaction effects between group and hour (F9,117 = 1.1, P = NS).
DISCUSSION
These data document the hourly change in PMDD symptoms over several days after
treatment with an SRI. Symptoms improved within 48 hr after starting treatment. We also
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noted a significant effect of time of day (independent of the day of treatment) suggesting
that symptoms improved over the day. Additionally, the rapid response was observed in all
four symptoms measured and, therefore, was not limited to the symptom of irritability.
Finally, we observed an identical temporal pattern of symptom remission after the initiation
of SRI treatment as that observed after the onset of menses.
Our data chronicle the hourly changes in mood symptoms after treatment with fluoxetine in
women with PMDD. Although the majority of women responded 48 hr after starting
fluoxetine, the time taken to achieve clinical response ranged from 1 to 6 days (Fig. 4).
Notwithstanding the range of times to meet response criteria, all women responded in a
much shorter time than would be predicted from studies of SRIs in the treatment of
depressive or anxiety disorders. In a previous placebo-controlled trial, a rapid improvement
in the symptom of irritability after 20 mg of paroxetine was demonstrated in 22 women with
PMDD,[2] and by the end of the third day of treatment, women were more likely to meet
criteria for clinical response and the average VAS irritability scores were significantly lower
on active drug compared with placebo. Although not placebo-controlled, our data are
consistent with these findings as well as those from Kornstein et al.[1] who reported the
efficacy of symptom-onset treatment with low-dose sertraline in women with PMDD under
placebo-controlled conditions. We observed a significant improvement from baseline scores
on the PMTS ratings on the morning of Day 3 of treatment (i.e. 48 hr after treatment
started); however, both our data and those of Landen[2] show individual differences in the
time taken to achieve clinical response to SRI treatment.
The rapidity of improvement after ingesting fluoxetine parallels observations of an acute
improvement in PMDD within hours after either oral m-CPP[3] or fenfluramine[11]
administration. The acute remission of symptoms after either m-CPP or fenfluramine,
however, was not maintained, and, therefore, a sustained therapeutic effect may require
several days of repeated administration of the drug, consistent with reports of the absence of
therapeutic benefits after a single high dose of fluoxetine administered during the luteal
phase in PMDD.[12]
In the study by Landen et al.,[2] the authors suggest that the rapid therapeutic effects of SRIs
in PMDD are most robustly demonstrated in the symptom of irritability. However, we
observed rapid and significant improvements in the VAS scores of anxiety, sadness, and
mood swings as well as irritability. The women with PMDD in the Landen study were
selected on the basis of the prominence of irritability in their clinical presentation and self
ratings,[2] whereas the women in our study could meet PMDD criteria in any one of the four
affective symptoms measured in the study.
In addition to improvements in all four symptoms over each day of treatment, we also
observed an effect of the hour at which ratings were completed during the day, with an
improvement in all VAS symptom ratings from morning to night during each day of therapy.
Upon review of the averages of the hourly VAS ratings, we observed with few exceptions
that on each day of treatment the worse scores (i.e. lowest) and best scores were in the first
and second halves of the day, respectively. However, this difference in the earlier versus the
later ratings was present on the first day of treatment, did not differ as a function of the
duration of treatment, and was similar to the pattern of change in symptom severity observed
in the untreated comparison group. A similar phenomenon was observed in the study by
Landen et al.[2] on the first day after the administration of paroxetine.
A rapid symptom response, similar to that seen post-SRI, also was observed during the 3
days after mensesonset in a separate group of untreated women with PMDD. The acute
improvement occurred in all four symptoms measured, with no difference between treated
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and untreated women in the hourly or daily change in symptoms during the 3 days
evaluated. These similarities in response might simply reflect a generic “switch-out” from
the symptomatic state in women with PMDD in response to either successful SRI treatment
or menses (or the luteal-follicular transition). Additionally, we observed considerable
interindividual variation in the rapidity of the switch-out after both SRIs and menses. Thus,
the kinetics of the switch-out in PMDD could reflect a phenotype reflecting how quickly a
woman’s affective state can change in response to a perturbation; SRIs could recruit this
capacity to change affective state and advance the switch-out that normally occurs after
menses-onset. Finally, the switch-out related to either SRI treatment or the onset of menses
could reflect a shared biology in a process fundamental to symptom relief in these women
with PMDD. In a previous study,[13] we demonstrated that terminating the luteal phase and
inducing menses with the progesterone receptor antagonist RU-486 had no effect on
symptoms in PMDD. Indeed, to the contrary, symptoms proceeded as they would have
occurred had normal luteal function been preserved. Thus, symptom remission in women
with PMDD does not appear to simply depend on the termination of corpus luteum function,
declining estradiol and progesterone levels, or the onset of menses. The characteristic
symptom remission in PMDD within a few days after the onset of menses, therefore, must
involve some as yet identified biological process that would mimic the mechanism of action
of SRIs in PMDD. One possibility is that both SRIs and events surrounding menses (and the
end of the luteal phase) increase central serotonergic system function. Indeed, Landen et
al.[2], suggest that an acute increase in serotonin is sufficient to improve symptoms in
PMDD, whereas a more prolonged incremental process involving 5HT1A autoreceptor
down regulation, serotonin transporter protein inhibition, and alterations in neuronal
plasticity underlies the therapeutic effects of SRIs in depression. Alternately, Pinna et al.[14]
argue that the rapid therapeutic effects of low-dose SRIs is mediated through increased CNS
neurosteroid synthesis (and presumed increased GABAA receptor function) and not by an
increase in serotonergic system function. The actions of both SRIs and menses to induce a
remission of PMDD symptoms, then, could be mediated by increased GABA activity. The
serotonin system—in particular, the 5-HT1A receptor—and GABAergic activity share
reciprocal relationships, with reductions in serotonin receptor function associated with
increased GABA activity in the amygdala.[15–18] Thus, an acute increase in GABA function,
secondary to increased neurosteroid production, could rapidly down regulate 5-HT1A
receptor function, and be the more proximate mechanism responsible for the therapeutic
action of SRIs in PMDD. Ambiguity about the mechanism of action notwithstanding, the
striking similarity of the kinetics observed between SRIs and menses suggests that
elucidation of underpinnings of the therapeutic response to SRIs in PMDD may shed light
on a naturally occurring affective switch, the menses.
Although this study clearly demonstrates the rapid response of core PMDD symptoms to
SRIs on both a daily and hourly basis, it has several limitations. First, it is not placebo
controlled and, therefore, we cannot distinguish the component of the observed therapeutic
response mediated by the nonspecific effects of medication administration. Numerous
placebo-controlled studies have demonstrated the effects of SRIs in this condition,[1,19–32]
and it was not the intention of this study to demonstrate the superior efficacy of SRIs
compared with placebo. Nonetheless, these data legitimately portray the open-label clinical
use of these medications in PMDD, and a similar time course also was observed by Landen
et al.[2] under placebo-controlled conditions. As a caveat, however, the rapidity of the
symptom response to SRIs in PMDD should not be generalized to either women with a
premenstrual exacerbation of an Axis 1 psychiatric condition or those women with PMDD
with a comorbid depressive illness. Second, the results are derived from a small sample size,
and the different timing of the onsets of symptoms during the luteal phase and during
menses led to variation in the numbers of days of ratings completed by each woman. Finally,
confidence would be increased in our observations of a “diurnal-like” improvement in the
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hourly symptom ratings after the start of fluoxetine had we obtained hourly ratings for more
days prior to treatment. This was not possible since women started treatment several days
after symptoms arose; however, a comparison group of untreated or placebo treated women
who rated during the same time intervals could serve to address this question.
In summary, these data demonstrate the rapid symptom improvement in women with
PMDD, consistent with placebo-controlled studies of symptom-onset SRI treatment of
PMDD.[1] The important contribution of these data is the elucidation and confirmation of
the time course of the symptom response, which commences on the first day of treatment,
progresses each day with peak responsivity 48 hr after treatment, and is maintained
thereafter until the onset of menses. The mechanism underlying the rapid effects of SRIs in
PMDD remains to be determined; however, these data suggest that it is not solely secondary
to an acute improvement in irritability. The similarities between the symptomatic response
to initiation of an SRI and to the onset of menses in untreated symptomatic women suggest
that a shared mechanism may lead to the switch-out from the symptomatic state in women
with PMDD. Enhanced neurosteroid activity possibly may mediate this switch-out, an
hypothesis that could be tested by using specific inhibitors of neurosteroid synthetic
enzymes to attempt to reverse the effects of fluoxetine in women with PMDD. Finally, it
remains to be determined whether the latencies to response to SRIs identify meaningful
phenotypic differences in PMDD.
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Figure 1.
Scores on the rating scale for PMTS (mean + SEM) were significantly improved compared
with baseline on the second day after the start of SRI treatment (Day 1). Improvement was
maintained until menses (ANOVA-R: F4,40 = 9.1, P = .001; Bonferroni t ≤ 3.8, df = 40, P ≤ .
01). Seven of 12 women experienced a 50% reduction relative to baseline within 2 days of
treatment.
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Figure 2.
Hourly VAS ratings of sadness and irritability for 10 hr each day prior to and after the start
of treatment with fluoxetine 20 mg daily on the morning of Day 1 (mean + SEM). Ratings
on the VAS scales showed a significant improvement after SRI in the symptoms of
irritability, as well as anxiety, sadness, and mood swings after the start of treatment that did
not differ across individual symptoms. (ANOVA-R: main effect of symptom type F3,30 =
0.9, P = NS, symptom × day interaction F15,150 = 1.8, P = .2), symptom × day ×hour
interaction F135,1350 = 1.0, P = .5). There also was significant improvement in the symptom
severity from the first to the last ratings of the day regardless of symptom or day of
treatment.
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Figure 3.
Three-point moving averages of the hourly VAS rating of irritability in women with PMDD
who were treated with fluoxetine during the luteal phase, and women with PMDD who
received no treatment. Ratings in women receiving fluoxetine represent pretreatment ratings
(Day −2, −1) and after receiving fluoxetine 20 mg daily in morning on Day 1, whereas
ratings in untreated women represent ratings premenses (Day −2, −1) and after the onset of
menses (Day 1). The onset of menses and the initiation of SRI treatment were accompanied
by similar patterns of symptom response (ANOVA-R of the ratings for all four symptoms
during Day 1–3 demonstrated an identical pattern of symptom improvement with significant
effects of both day and hour that reflected an improvement in scores of all four symptoms
after the onset of either SRI treatment or menses (main effect of day F2,32 = 8.3, P = .003;
main effect of hour F9,144 = 5.9, P < .001).
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Figure 4.
Examples of symptom remission (i.e. switch-out) characteristics after SRI treatment in three
separate patients: (1) a gradual remission of symptoms over 5 to 6 days, (2) moderately
rapid symptom remission over 2 to 3 days, and (3) a switch-out of the symptomatic state
within 24 hr.
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